Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
May 15, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular...
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
March 13, 2023 07:00 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
February 14, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
Pre-launch commercial activities underway as Company advances toward U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010 /...
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
February 07, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
January 19, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
January 09, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
December 29, 2022 09:05 ET
|
Outlook Therapeutics, Inc.
Attained U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic...
Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note
December 23, 2022 09:00 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 23, 2022 06:00 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...